US4659805A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Recombinant alveolar surfactant protein
Assignee: Takeda GmbH
•
Filing: 1984-12-11
•
Granted: 1987-04-21
•
Expires: 2004-12-11
Abstract
Abstract The complete coding sequences and amino acid sequences for both canine and human alveolar surfactant protein (ASP) are disclosed. Methods and vectors for obtaining these proteins in recombinant form are described. The availability of large amounts of these proteins through recombinant techniques permits the use of ASP in suitable pharmaceutical compositions in the treatment of respiratory deficiency syndromes.
Inventors
- 👤 James W. Schilling, Jr.
- 👤 Robert T. White
- 👤 Barbara Cordell
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 13:34
CPC Classifications
C; C07; C07K; C07K14/00; C07K14/435; C07K14/785; A; A61; A61P; A61P11/00; A61K; A61K38/00; Y; Y10; Y10S; Y10S930/00; Y10S930/01; Y10S930/30
Claims Analysis
Total Claims: 16
Claim 1
Independent Claim
96 words
Human alveolar surfactant protein (ASP) in substantially pure form having the amino acid sequence encoded by the DNA shown in FIG. 3 as exon II-IV DNA and that portion of the exon I DNA encoding mature ASP amino acid sequence. and by the naturally occurring allelic variants thereof, wherein the ASP is selected from the group consisting of the aforesaid directly encoded amino acid sequence, and said directly encoded amino acid sequence wherein at least one proline residue is substituted for by a hydroxypyroline residue, and wherein said ASP may be in glycosylated or unglycosylated form.
Claim 2
Dependent Claim
96 words
Human alveolar surfactant protein (ASP) in substantially pure form having the amino acid sequence encoded by the DNA shown in FIG. 3 as exon II-IV DNA and that portion of the exon I DNA encoding mature ASP amino acid sequence. and by the naturally occurring allelic variants thereof, wherein the ASP is selected from the group consisting of the aforesaid directly encoded amino acid sequence, and said directly encoded amino acid sequence wherein at least one proline residue is substituted for by a hydroxypyroline residue, and wherein said ASP may be in glycosylated or unglycosylated form.
Claim 3
Dependent Claim
17 words
The ASP of claim 1 wherein at least three proline residues are substituted for by hydroxyproline residues.
Claim 4
Dependent Claim
15 words
The ASP of claim 2 wherein all proline residues are substituted for by hydroxyproline residues.
Claim 5
Dependent Claim
81 words
Canine alveolar surfactant protein (ASP) in substantially pure form having the amino acid sequence encoded by the DNA sequence shown as encoding mature ASP in FIG. 1 and by the naturally occurring allelic variants thereof, wherein as ASP is selected from the group consisting of the aforesaid directly encoded amino acid sequence and said directly encoded amino acid sequence wherein at least one proline residue is substituted for by a hydroxyproline, and wherein said ASP is in glycosylated or unglycosylated form.
Claim 6
Dependent Claim
81 words
Canine alveolar surfactant protein (ASP) in substantially pure form having the amino acid sequence encoded by the DNA sequence shown as encoding mature ASP in FIG. 1 and by the naturally occurring allelic variants thereof, wherein as ASP is selected from the group consisting of the aforesaid directly encoded amino acid sequence and said directly encoded amino acid sequence wherein at least one proline residue is substituted for by a hydroxyproline, and wherein said ASP is in glycosylated or unglycosylated form.
Claim 7
Dependent Claim
16 words
The ASP of claim 4 wherein at least four hydroxyproline residues are substituted for by hydroxyproline.
Claim 8
Dependent Claim
14 words
The ASP of claim 5 wherein all proline residues are substituted for by hydroxyproline.
Claim 9
Dependent Claim
28 words
A pharmaceutical composition effective in treating respiratory distress syndrome (RDS) in mammals, which composition comprises the human ASP of claim 1 in admixture with a pharmaceutically acceptable excipient.
Claim 10
Dependent Claim
36 words
A method of treating respiratory distress syndrome in mammals which comprises administering to a subject mammal in need of such treatment an effective amount of human ASP of claim 1 or a pharmaceutical composition containing it.
Claim 11
Dependent Claim
21 words
A pharmaceutical composition comprising the human ASP of claim 1 in the form of a complex with natural or synthetic lipids.
Claim 12
Dependent Claim
19 words
The composition of claim 9 wherein the complex is comprised of between about 50% and almost 100% (wt/wt) lipid.
Claim 13
Dependent Claim
12 words
The composition of claim 10 wherein the complex contains approximately 80-95% lipid.
Claim 14
Dependent Claim
19 words
The composition of claim 9 wherein the lipid portion of the complex is approximately 80-90% dipalmitoyl phosphatidyl chlorine (DPPC).
Claim 15
Dependent Claim
27 words
The composition of claim 12 wherein the lipid portion of the complex also contains a unsaturated phosphatidyl choline, phosphatidyl glycerol, triacyl glycerol, palmitic acid, or mixtures thereof.
Claim 16
Dependent Claim
14 words
The composition of claim 9 which further includes at least one pharmaceutically acceptable excipient.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1990-04-20 | 1990-10-20 | 1991-04-21 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1994-04-20 | 1994-10-20 | 1995-04-21 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1998-04-20 | 1998-10-20 | 1999-04-21 | $7700.00 | Window Closed / Lapsed |